Cardiology remains one of the more heavily scrutinized specialties in federal billing oversight, and 2026 brought a specific, significant development: an OIG report finding that roughly $105 million in Medicare Part B payments for office-based peripheral vascular procedures may represent medically unnecessary billing. Beyond that, cardiology’s recurring compliance risks center on diagnostic testing supervision requirements, documentation that doesn’t clearly support medical necessity, and modifier use on combined procedures. None of these risks are new in concept, but 2026’s specific findings and priorities make them more immediate.
The OIG’s 2026 Peripheral Vascular Procedure Findings
In May 2026, OIG published a report examining Medicare Part B billing for office-based peripheral vascular procedures, angioplasty, stenting, and atherectomy performed to treat peripheral artery disease. Medicare Part B paid over $1 billion for these procedures in 2022, and OIG found that physicians have increasingly shifted this work into office-based laboratories, where Medicare payments to physicians run higher than in other settings. Of the payments made to office-based laboratory physicians for these procedures, OIG identified approximately $105 million that may indicate billing for medically unnecessary services.
This matters directly for interventional and vascular cardiology, since these are among the specialties that perform these specific procedures. OIG identified the flagged billing using claims-based measures, including unusually high rates of more invasive tibial procedures and a high average number of procedures per patient, and recommended that CMS follow up directly with the specific physicians it identified. As of September 10, 2026, CMS formally concurred with that recommendation, according to OIG’s own recommendations tracker, meaning it’s actively moving forward rather than sitting unaddressed. Both of OIG’s recommendations from this report remain open as of this writing, with CMS’s next update expected November 3, 2026.
It’s worth noting the findings haven’t gone unanswered. In June 2026, several vascular and interventional specialty societies issued a joint statement responding to the report, agreeing on the need for appropriate, evidence-based PAD care while arguing that parts of the report’s methodology and clinical framing require more careful interpretation. That pushback doesn’t change the underlying billing patterns OIG identified, but it’s a reasonable reminder that being flagged by one of the claims-based measures isn’t the same as a confirmed finding of improper billing. Practices performing these procedures in an office-based setting should still treat this as a direct, active signal to review their own billing patterns against the measures OIG used, rather than assume the report doesn’t apply to them.
Diagnostic Testing Supervision Requirements
Cardiology relies heavily on diagnostic testing, stress tests, echocardiograms, nuclear cardiology studies, and each of these services has its own physician supervision level requirement under Medicare rules. Billing a diagnostic test without the documentation to support that the required supervision level was actually met, whether that’s general, direct, or personal supervision depending on the specific test, is a recurring compliance exposure that’s distinct from a simple coding error, since it goes to whether the service was furnished in compliance with the conditions for payment at all, not just whether it was coded correctly.
Modifier 25 and the Broader 2026 OIG Focus
Modifier 25 remains a named federal priority for 2026, with OIG examining E/M claims billed alongside minor procedures where documentation needs to clearly support a significant, separately identifiable evaluation. This applies across specialties, but it’s a particularly common pattern in cardiology, where a diagnostic procedure and an E/M evaluation frequently happen in the same visit. The compliance risk isn’t using modifier 25 itself; it’s using it on a visit where the note doesn’t actually distinguish the separate evaluation from the routine work already built into the procedure.
Documentation That Doesn’t Clearly Support Medical Necessity
A recurring theme across cardiology audit findings, from the peripheral vascular report to general OIG and payer reviews, is documentation that doesn’t clearly establish why a specific procedure was medically necessary for that specific patient. For procedures like peripheral vascular interventions, this increasingly means documenting that conservative management, medication optimization, supervised exercise therapy, and lifestyle modification, were attempted and considered before proceeding to an invasive procedure, not just documenting the diagnosis that justified it in general terms.
A Quick Compliance Checklist
| Risk Area | What to Confirm |
| Peripheral vascular procedures in OBL settings | Review billing patterns against OIG’s flagged measures; confirm conservative management was documented before intervention |
| Diagnostic testing supervision | Confirm the required supervision level was met and documented for each specific test type |
| Modifier 25 on combined visits | Confirm documentation clearly separates the E/M evaluation from routine procedure work |
| Medical necessity documentation | Confirm the note establishes necessity for this specific patient and procedure, not just a general diagnosis |
| Internal audit cadence | Review high-risk billing patterns regularly rather than waiting for an external audit to surface issues |
Conclusion
Staying ahead of cardiology’s specific compliance risks depends on accurate coding and documentation review built into the billing workflow, not just a response after an audit arrives. Rapid RCM Solutions supports this through its coding and reporting services, helping cardiology practices review billing patterns and documentation before they draw the kind of attention OIG’s 2026 findings describe.
FAQs
Does the OIG’s peripheral vascular procedure report apply to all cardiology billing?
No, it’s specific to office-based peripheral vascular procedures, angioplasty, stenting, and atherectomy, most relevant to interventional and vascular cardiology practices billing these services in an office-based laboratory setting, not cardiology billing broadly.
What did OIG actually recommend in the 2026 report, and where does it stand now?
OIG recommended that CMS monitor billing to identify peripheral vascular procedures that may be medically unnecessary, and follow up directly with the specific physicians OIG identified as having concerning billing patterns. As of September 10, 2026, CMS formally concurred with the recommendation to follow up with those physicians, though both recommendations remain officially open as implementation continues, with the next OIG update expected in early November 2026.
Why does diagnostic testing supervision matter for compliance, separate from coding accuracy?
Supervision requirements are a condition of payment, not just a coding detail. A diagnostic test billed without meeting and documenting the required supervision level can be a compliance issue even if every code on the claim is technically correct.
What’s the safest way for a cardiology practice to respond to this OIG report?
Reviewing internal billing patterns against the measures OIG used to flag physicians, rather than assuming the report doesn’t apply, is the more defensible position. The report reflects billing pattern analysis, not a finding that every flagged physician committed fraud, a distinction several specialty societies raised directly in a June 2026 joint statement, but it signals exactly where federal attention is currently focused.
